To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of olanzapine as a treatment for schizophrenia and to determine the advantages and disadvantages of this atypical antipsychotic agent compared with currently marketed agents.
DATA SOURCES:
A MEDLINE computer literature search was conducted to retrieve all English-language studies and review articles involving olanzapine published as of October 1, 1996. The manufacturer of the drug, Eli Lilly and Company, provided the clinical investigator's brochure and abstracts of unpublished Phase III clinical trials.
STUDY SELECTION:
Animal studies evaluating the pharmacology of olanzapine were evaluated, as were all open-label and double-blind studies involving the evaluation of olanzapine for the treatment of patients with schizophrenia.
DATA EXTRACTION:
All available clinical studies were reviewed and the interpretation of data for each study was influenced by the size of the study sample, the nature of the inclusion and exclusion criteria, and the data analysis techniques used.
DATA SYNTHESIS:
Olanzapine is a thienobenzodiazepine analog with an in vitro receptor affinity profile similar to that of clozapine. Olanzapine exhibits linear kinetics over the dosage range studied and is extensively metabolized in humans. Clinical evaluations to date have shown olanzapine to be at least as efficacious as typical antipsychotic agents in the treatment of the acute phase of schizophrenia. The drug was well tolerated, with significantly fewer extrapyramidal adverse effects than haloperidol. Current data suggest that olanzapine may be more effective than haloperidol for the treatment of negative symptoms; moreover, preliminary data suggest that fewer relapses occur over the course of treatment in patients treated with olanzapine compared with those taking haloperidol.
CONCLUSIONS:
The exact place of olanzapine in the therapy of psychotic patients remains unclear, as more data are needed to evaluate the long-term efficacy of this agent, its impact on negative symptoms, and its potential use in patients resistant to the standard agents. Despite limitations in the current database, olanzapine is a promising treatment option for patients with schizophrenia.
DonaldsonSRGelenbergAJBaldessariniRJ. The pharmacological treatment of schizophrenia: a progress report. Schizophr Bull1983; 9: 504–27.
2.
HogartyG. Treatment and course of schizophrenia. Schizophr Bull1977; 3: 587–99.
3.
BreierASchreiberJDyerJPickarD. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry1991; 48: 239–46.
4.
SovnerRDiMascioA. Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: LiptonMADiMascioAKillamF, eds. Psychopharmacology: a generation of progress. New York: Raven Press1978: 1021–32.
5.
BaldessariniRJ. A summary of current knowledge of tardive dyskinesia. Encephale1988; 14: 263–8.
6.
LevensonJ. Neuroleptic malignant syndrome. Am J Psychiatry1985; 142: 1137–45.
7.
KaneJMHoningfeldGSingerJMeltzerHY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry1988; 45: 789–96.
MeltzerHY. Suicidality and clozapine. J Clin Psychiatry Monograph1996; 14: 13–5.
10.
MeltzerHYOkayliG. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry1995; 152: 183–90.
11.
MeltzerHY. Clozapine and other atypical neuroleptics: efficacy, side effects, optimal utilization. J Clin Psychiatry1994; 12: 38–42.
12.
MeltzerHYColaPA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry1994; 55 (9, suppl B): 161–5.
13.
MeltzerHYColaPWayLThompsonPABastaniBDaviesMA. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry1993; 150: 1630–8.
14.
BaldessariniRJFrankenburgFR. Clozapine, a novel antipsychotic agent. New Engl J Med1991; 324: 746–54.
15.
ClausABollenJDeCuyperHEnemanMMalfroidMPeuskensJ. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand1992; 85: 295–305.
16.
ChouinardGJonesBRemingtonGBloomDAddingtonDMacEwanGW. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol1993; 13: 25–40.
17.
CardoniAA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother1995; 29: 610–8.
18.
CavallaroRColomboCSmeraldiE. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol1995; 10: 231–4.
19.
LaceyRLPreskornSHJerkovichGS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics (letter)?. Am J Psychiatry1995; 152: 1401.
20.
SatterleeWDellvaMABeaselyCMTranDVCousinsLMTollefsonGD. Effectiveness of olanzapine in long-term continuation therapy (poster). Presentation at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, 1996.
MooreNATyeNCAxtonMSRisiusFC. The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic. J Pharmacol Exp Ther1992; 262: 545–51.
23.
BymasterFPCalligaroDOFalconeJF. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology1996; 14: 87–96.
24.
SailerCFSalamaAI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology1993; 112: 285–92.
25.
EreshefskyLLaCombeS. Pharmacological profile of risperidone. Can J Psychiatry1993; 38 (suppl 3): S80–8.
26.
FullerRWSnoddyHD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol1992; 77: 87–93.
27.
StocktonMERasmussenK. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology1996; 14: 97–104.
28.
WhiteFJWangRY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science1983; 221: 1054.
29.
CoyleJT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry1996; 3: 241–53.
30.
OlneyJWFarbeNB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry1995; 52: 998–1007.
31.
BakshiVPGeyerMA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology1995; 122: 198–201.
32.
ObermeyerBDNyhartEHJrMattiuzELGoodwinRMBartonRDBreauAP. The disposition of olanzapine (OL) in healthy volunteers. Pharmacologist1993; 35: 176.
33.
Package insert Olanzapine. Indianapolis, IN: Eli Lilly and Co., 1996.
34.
RingBJCatlowJLindsayTJGillepsieTRoskosLKCerimeleBJ. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther1996; 276: 658–66.
35.
PatelBRNyhartEHCallaghanJTKassahunKHuntTLKurtzD. Combined population analysis of olanzapine in healthy volunteers. Pharm Res1995; 12: S-415.
36.
BergstromRFCallaghanJTCerimeleBJNyhartEHKassahunkHuntTL. Pharmacokinetics of olanzapine in elderly and young. Pharm Res1995; 12: S-358.
37.
BeasleyCMJrTollefsonGTranPSatterleeWSangerTHamiltonS. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology1996; 14: 111–23.
38.
BeasleyCMJrSangerTSatterleeWTolfesonGTranPHamiltonS. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology1996; 124: 159–67.
39.
BeasleyCMJrHamiltonSHCrawfordAMDellvaMATollefsonGDTranPV. Acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol1997; 7: 125–37.
40.
TollefsonGDBeasleyCMTranPVStreetJSKruegerJATamaraRN. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry1997; 154: 457–65.
AndreasenNC. Negative symptoms in schizophrenia. Arch Gen Psychiatry1982; 39: 784–8.
43.
TollefsonGLuY. Comorbid mood disturbance in schizophrenia (poster). Presented at the Collegium International Neuro-Psychopharmacologicum (CINP), Melbourne, Australia, 1996.
44.
TranPBeasleyCMTollefsonGCrawfordAMDellvaMAGusmanS. Acute and long-term results of the dose ranging double-blind olanzapine trial (poster). Presented at the Collegium International Neuro-Psychopharmacologicum (CINP), Melbourne, Australia, 1996.
45.
TranPVBeasleyCMDellvaMACousinsLMGusmanSTollefsonGD. Long-term efficacy and safety of olanzapine (poster). Presented at the American Psychiatric Association Meeting, Washington, DC, 1995.
46.
TranPVBeasleyCMDellvaMACousinsLMGusmanSTTollefsonGD. Long-term efficacy and safety of olanzapine (poster). Presented at the American College of Neuropsychopharmacology (ACNP) meeting, San Juan, Puerto Rico, 1995.
47.
RingBJBinkleySNVanderbrandenMWrightonSA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2D6, and CYP3A. Br J Clin Pharmacol1996; 41: 181–6.
48.
FlockhartDA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic?. J Clin Psychopharmacol1996; 16: 101–2.
49.
BergstromRFCallaghanJTCerimeleBJNyhartEHJrKassahunKHuntTL. Pharmacokinetics of olanzapine in elderly and young (abstract). Pharm Res1995; 12: S358.
50.
SatterleeWUnpublished report: olanzapine in elderly psychotic patients. Indianapolis, IN: Eli Lilly and Co., 1996.
51.
TranPVTollefsonGHamiltonSKuntzA. Olanzapine vs. risperidone in the treatment of psychosis. Preliminary report (poster). Presented at the American College of Neuropharmacology (ACNP) meeting, San Juan, Puerto Rico, 1996.
52.
MarderSRMeibachRC. Risperidone in the treatment of schizophrenia. Am J Psychiatry1994; 151: 825–35.
53.
KaneJMCooperTBSacharEJHalpernFSBailineSL. Clozapine plasma levels and prolactin response. Psychopharmacology1981; 73: 184–7.
54.
JesteDVWyattRJUnderstanding and treating tardive dyskinesia. New York: Guildord Press, 1982.
55.
AddingtonDEToewsJAAddingtonJM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry1995; 56: 484–5.
56.
KaneJMWoernerMGPollackSSaffermanAZLiebermannJA. Does clozapine cause tardive dyskinesia?. J Clin Psychiatry1993; 54: 327–30.
CarpenterWTJrConleyRRBuchananRWBreierATammingaCA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry1995; 152: 827–32.
59.
HallerEBinderRL. Clozapine and seizures. Am J Psychiatry1990; 147: 1069–71.
AddingtonDEJonesBBloomDChouinardGRemingtonGAlbrightP. Reduction of hospital stays in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther1993; 15: 917–26.
